NCT02274623View on ClinicalTrials.gov

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 27, 2017

Study Completion Date

March 17, 2017

Conditions
Breast CancerProstate CancerBone NeoplasmsHypocalcemiaHyperparathyroidism, Secondary
Interventions
DRUG

CTAP101 Capsules

escalating doses

Trial Locations (6)

14263

Roswell Park Cancer Institute, Buffalo

22031

Inova Dwight and Martha Schar Cancer Center, Fairfax

33140

Mount Sinai Medical Center, Comprehensive Cancer Center, Miami

45267

University of Cincinnati Cancer Institute, Cincinnati

60805

Research by Design LLC, Evergreen Park

90806

Coast Hematology-Oncology Associates, Long Beach

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT02274623 - Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid | Biotech Hunter | Biotech Hunter